This article was originally published in The Gray Sheet
Privately held distributor of specialty medical products envisions an initial public offering after revenues increase to $250 mil., the firm states in a Dec. 14 release. With current projected sales of $115 mil., the firm has expanded its geographic coverage to the West Coast by acquiring Redmond, Washington-based specialty distributor Omnimedical. "The acquisition gives HTD a presence in 30 states with coverage of 67% of the U.S. population," the company says. HTD was formed in May 1998 through the merger of four medical specialty distributors including Triad Medical, Bimeco, Futuretech and MegaTech Medical
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.